October 2024 KRX Growth Stocks With High Insider Confidence

Simply Wall St · 10/18 05:34

Despite recent fluctuations, the South Korean stock market has shown resilience, with the KOSPI index hovering just below the 2,610-point mark amid mixed performances across sectors. In this environment, growth companies with high insider ownership are particularly noteworthy as they often signal strong internal confidence and potential stability amidst broader market volatility.

Top 10 Growth Companies With High Insider Ownership In South Korea

Name Insider Ownership Earnings Growth
People & Technology (KOSDAQ:A137400) 16.4% 35.6%
Seojin SystemLtd (KOSDAQ:A178320) 30.8% 49.1%
ALTEOGEN (KOSDAQ:A196170) 26.6% 99.5%
Bioneer (KOSDAQ:A064550) 15.8% 97.6%
Oscotec (KOSDAQ:A039200) 26.1% 122%
HANA Micron (KOSDAQ:A067310) 18.3% 105.8%
Vuno (KOSDAQ:A338220) 19.4% 110.9%
INTEKPLUS (KOSDAQ:A064290) 16.3% 96.7%
UTI (KOSDAQ:A179900) 33.1% 134.6%
Techwing (KOSDAQ:A089030) 18.7% 83.6%

Click here to see the full list of 86 stocks from our Fast Growing KRX Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Oscotec (KOSDAQ:A039200)

Simply Wall St Growth Rating: ★★★★★★

Overview: Oscotec Inc. is a biotechnology company involved in drug development, functional materials, and dental bone graft materials, with a market cap of approximately ₩1.54 billion.

Operations: The company generates revenue from its Food Business Division (₩1.69 billion), Medical Business Sector (₩1.63 billion), New Drug Business Division (₩990.90 million), and Functional Materials Division (₩310.71 million).

Insider Ownership: 26.1%

Earnings Growth Forecast: 122% p.a.

Oscotec is expected to experience significant growth, with earnings forecasted to increase by 122% annually and revenue projected to rise at 68.9% per year, outpacing the South Korean market. The company is trading at a substantial discount, 38.7% below its estimated fair value. Despite these promising growth metrics, Oscotec's current revenue remains relatively low at ₩5 billion and its share price has been highly volatile over the past three months.

KOSDAQ:A039200 Earnings and Revenue Growth as at Oct 2024
KOSDAQ:A039200 Earnings and Revenue Growth as at Oct 2024

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company that specializes in developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩20.40 trillion.

Operations: The company generates revenue primarily from its biotechnology segment, totaling ₩90.79 billion.

Insider Ownership: 26.6%

Earnings Growth Forecast: 99.5% p.a.

ALTEOGEN is trading at a significant discount, 70.5% below its estimated fair value, with earnings expected to grow by 99.46% annually. The company is projected to become profitable within three years, surpassing average market growth rates. Revenue growth is forecasted at 64.2% per year, well above the South Korean market average of 10.3%. However, the share price has been highly volatile recently and shareholders experienced dilution over the past year.

KOSDAQ:A196170 Ownership Breakdown as at Oct 2024
KOSDAQ:A196170 Ownership Breakdown as at Oct 2024

SOCAR (KOSE:A403550)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: SOCAR Inc. is a mobility company based in South Korea with a market capitalization of ₩593.20 billion.

Operations: The company's revenue is primarily generated from car sharing, which accounts for ₩372.90 billion, followed by micro mobility at ₩22.03 billion and platform parking services contributing ₩7.80 billion.

Insider Ownership: 13.7%

Earnings Growth Forecast: 106.1% p.a.

SOCAR is trading at a substantial discount, 88% below its estimated fair value. Despite reporting increased net losses recently, the company is expected to achieve profitability within three years, outperforming average market growth. Revenue is anticipated to grow at 18% annually, faster than the South Korean market's average of 10.3%. Analysts agree on a potential stock price increase of 47.5%, although return on equity remains low with forecasts at just 7.1%.

KOSE:A403550 Ownership Breakdown as at Oct 2024
KOSE:A403550 Ownership Breakdown as at Oct 2024

Seize The Opportunity

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.